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Abstract
Introduction: Clinical trials have demonstrated that treatment-to-target (T2T) is effective in achieving remission in
early rheumatoid arthritis (RA). However, the concept of T2T has not been fully implemented yet and the question
is whether a T2T strategy is feasible in daily clinical practice. The objective of the study was to evaluate the
adherence to a T2T strategy aiming at remission (Disease Activity Score in 28 joints (DAS28) < 2.6) in early RA in
daily practice. The recommendations regarding T2T included regular assessment of the DAS28 and advice
regarding DAS28-driven treatment adjustments.
Methods: A medical chart review was performed among a random sample of 100 RA patients of the DREAM
remission induction cohort. At all scheduled visits, it was determined whether the clinical decisions were compliant
to the T2T recommendations.
Results: The 100 patients contributed to a total of 1,115 visits. The DAS28 was available in 97.9% (1,092/1,115) of
the visits, of which the DAS28 was assessed at a frequency of at least every three months in 88.3% (964/1,092).
Adherence to the treatment advice was observed in 69.3% (757/1,092) of the visits. In case of non-adherence when
remission was present (19.5%, 108/553), most frequently medication was tapered off or discontinued when it
should have been continued (7.2%, 40/553) or treatment was continued when it should have been tapered off or
discontinued (6.2%, 34/553). In case of non-adherence when remission was absent (42.1%, 227/539), most
frequently medication was not intensified when an intensification step should have been taken (34.9%, 188/539).
The main reason for non-adherence was discordance between disease activity status according to the
rheumatologist and DAS28.
Conclusions: The recommendations regarding T2T were successfully implemented and high adherence was
observed. This demonstrates that a T2T strategy is feasible in RA in daily clinical practice.
Introduction
New insights into the treatment of rheumatoid arthritis
(RA) have led to better care for RA patients, thereby
strongly improving outcome [1,2]. Herewith, clinical
remission has become the ultimate therapeutic goal in
RA [3]. Several studies have demonstrated that a treat-
ment approach including tight control of disease activity
is more effective in lowering disease activity and,
ultimately, reaching remission, compared with usual care
[4-8]. The major keystones of such a treat-to-target
(T2T) strategy are: 1) regular assessment of the disease
activity using a validated outcome measure, 2) subse-
quent adjustments of treatment in case of persistent dis-
ease activity, preferably following a medication protocol
where therapeutic consequences are predefined [9], and
3) aiming at a predefined target.
Current recommendations and guidelines on the man-
agement of RA address the importance of treating RA to
a target of remission or low disease activity [3,10]. In this
context, the European League Against Rheumatism
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(EULAR) has formulated a set of 10 international recom-
mendations on how to achieve optimal outcomes of RA
by providing guidance for T2T [11]. Although the rheu-
matology community worldwide endorses the impor-
tance of T2T [12], a lack of compliance with this issue is
presumed in daily clinical practice. It is assumed that dis-
ease activity is not consistently measured by validated
measures and medication is often not intensified or chan-
ged when disease is active in the routine care setting
[6,13-15].
The implementation of guidelines and the translation
of beneficial results of clinical trials to daily clinical
practice are considered to be difficult [16-19]. The ques-
tion is whether a T2T strategy, including protocolized
treatment adjustments will be feasible in a real-life set-
ting, which is characterized by a more heterogeneous
patient population [20], variation in prescription beha-
vior of specialists [19,21], and restriction of time, costs
and resources.
In 2006, six of the Dutch Rheumatoid Arthritis Monitor-
ing (DREAM) consortium hospitals implemented a T2T
strategy in the so-called DREAM remission induction
cohort. Four of these six hospitals successfully implemen-
ted the strategy and included at least 20 patients. Since the
day of diagnosis, very early RA patients were treated
according to a T2T strategy aiming at remission (defined
as a Disease Activity Score in 28 joints (DAS28) < 2.6 [22]),
including a treatment advice regarding subsequent DAS28-
driven therapeutic steps [23]. The aim of the present study
was to evaluate the adherence to these T2T recommenda-
tions. We examined whether these recommendations
resulted in regular assessment of the disease activity with
the DAS28 and whether medication was adapted according
to the treatment advice. Moreover, we explored reasons for
non-adherence to the T2T recommendations.
Materials and methods
Patients
Recommendations regarding T2T were implemented in six
hospitals in The Netherlands in January 2006, as part of the
DREAM remission induction cohort. Inclusion of patients
into the cohort and data collection are still on-going. The
cohort consists of consecutive patients newly diagnosed
with RA who met the following inclusion criteria: clinical
diagnosis of RA, age ≥ 18, symptom duration (defined as
time from first reported symptom to diagnosis of RA by
rheumatologist) of one year or less, a DAS28 ≥ 2.6, and no
previous treatment with disease-modifying antirheumatic
drugs (DMARDs) and/or prednisolone. Under Dutch law,
this descriptive evaluation does not need approval from an
ethical review board. Nonetheless, patients were fully
informed, and informed consent was obtained.
For the present study, a random sample of 100 patients
of the DREAM remission induction cohort was taken
using the ‘random sample of cases’ function in SPSS. We
selected patients who had a minimal follow-up of six
months to ensure that every patient had at least three fol-
low-up evaluations.
Treatment
After inclusion, visits were scheduled at weeks 8, 12, 20,
24, 36 and 52, and every three months thereafter. Patients
could visit the rheumatologist in between the scheduled
cohort visits when necessary. The T2T recommendations
included systematic monitoring of the disease activity with
the DAS28 in combination with a treatment advice regard-
ing predefined treatment adjustments aiming at remission
(defined as a DAS28 < 2.6). Therapy consisted of initial
methotrexate monotherapy (MTX), followed by the addi-
tion of sulfasalazine (SSZ) in case of non-remission, and
thereafter, sulfasalazine was exchanged for anti-tumor
necrosis factor (TNF)-a agents in case of moderate or
high disease activity (Table 1). If the target of DAS28 < 2.6
was reached, medication was not changed. In case of sus-
tained remission (six months or more), medication was
gradually tapered and eventually discontinued. The last
introduced medication was tapered off first (that is, MTX
was always tapered off as the last medication). The taper-
ing steps were as follows (all lasting six months): MTX in
mg/week, 25 to 15 to 7.5 to stop; SSZ in mg/day, 3,000 to
2,000 to 1,000 to stop; adalimumab 40 mg, every week to
every two weeks to stop; etanercept 50 mg, every week to
every two weeks to stop; infliximab 3 mg/kg, every four
weeks to every eight weeks to stop. In case of a disease
flare-up (DAS28 ≥ 2.6), the most recently effective medica-
tion (dosage) was reintroduced and treatment could be
subsequently intensified.
Deviations from the protocol were allowed on clinical
indication. In patients with a sulfa allergy, SSZ was
replaced by hydroxychloroquine at 400 mg per day. Non-
steroidal anti-inflammatory drugs, prednisolone ≤ 10 mg
per day and intra-articular corticosteroid injections were
allowed at clinical indication. Details of the protocol were
reported earlier [23]. All clinical data on patient character-
istics, clinical and laboratory measures, and medication
use were prospectively stored in an electronic database.
Measures
The following variables were collected at baseline: age, sex,
symptom duration, fulfilment of the American College of
Rheumatology (ACR) 1987 criteria for the classification of
RA [24], rheumatoid factor (RF) status, anti-cyclic citrulli-
nated peptide antibody status, C-reactive protein (CRP),
patient’s global assessment of pain on a 100-mm visual
analogue scale (VAS), the disability index of the Dutch
version of the Health Assessment Questionnaire [25,26],
and component summary scores for physical and mental
health of the 36-item Short Form Health Survey [27].
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At every visit, joint counts were performed by trained
rheumatology nurses, erythrocyte sedimentation rate
(ESR) was measured and general health was filled out
on a 100-mm VAS by the patient. The nurse calculated
the DAS28 score and provided this, including the values
of its components, to the rheumatologist.
Remission was defined as a DAS28 < 2.6. Remission
according to the provisional ACR/EULAR Boolean-based
definition of remission in RA was also examined, which
required a tender joint count in 28 joints (TJC28) ≤ 1, swol-
len joint count in 28 joints (SJC28) ≤ 1, CRP ≤ 1 mg/dl and
patient global assessment (PGA, on a 0 to 10 scale) ≤ 1 [28].
Data extraction
All scheduled clinical visits were retrieved from the data-
base and parameters for disease activity and medication
were extracted. A medical chart review was performed to
determine whether the clinical decisions were compliant
to the above described recommendations.
Deviations from the treatment advice were classified as:
not intensifying (that is, continuing/tapering off/disconti-
nuing) instead of intensifying treatment; intensifying
instead of not intensifying (that is, continuing/tapering off/
discontinuing) treatment; continuing instead of tapering
off/discontinuing treatment; tapering off/discontinuing
instead of continuing treatment; and other deviations. We
registered whether the deviations concerned conventional
DMARDs or anti-TNF therapy. Possible reasons for non-
adherence were retrieved from the medical chart. Medica-
tion use outside the treatment advice (including the use of
prednisolone dosages > 10 mg per day) was registered.
Statistical analysis
The primary outcome measures were the number of
cohort visits in which the DAS28 was assessed and the
number of these visits in which therapy was adapted
according to the treatment advice, stratified by remis-
sion state (yes/no). The various deviations were reported
as numbers with corresponding percentages. Pie charts
were used to graphically present the extent to which the
medication protocol was followed.
To test differences in the patient baseline characteris-
tics between hospitals, we used independent t tests for
normally distributed variables, chi-square tests for cate-
gorical variables and Mann-Whitney U tests for non-
normally distributed variables.
The level of significance was set at a P-value < 0.05. Sta-
tistical analyses were performed using the statistical soft-
ware package SPSS 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Study sample
The baseline characteristics of the 100 patients whose
medical charts were examined are presented in Table 2.
This study group reflects a normal early RA population
with 61.0% of the patients being female, a mean (standard
deviation, SD) age of 57.7 (15.4), 61.0% RF positivity, and a
mean DAS28 (SD) of 4.9 (1.1). Patients’ baseline character-
istics were comparable between hospitals (data not
shown), except for symptom duration which differed
between two hospitals; median (interquartile range, IQR)
of 10.0 (6.5 to 16.0) versus 21.0 (9.8 to 30.3) weeks, P =
0.012. The baseline characteristics of the patients who
were not included in this study did not differ significantly
or clinically relevantly from the random sample of patients
who were included in this study (not shown).
The 100 patients contributed to a total of 1,115 visits.
The mean (SD) follow-up time at the time of data collec-
tion in these patients was 28.0 (10.0) months. The mean
(SD) number of cohort visits per patient was 10.9 (3.6).
Table 1 Treatment protocol
Follow-up DAS28 Medication
Week 0 ≥ 2.6 Methotrexate 15 mg/wk
Week 8 ≥ 2.6 Methotrexate 25 mg/wk
Week 12 ≥ 2.6 Methotrexate 25 mg/wk + sulfasalazine 2,000 mg/day
Week 20 ≥ 2.6 Methotrexate 25 mg/wk + sulfasalazine 3,000 mg/day
Week 24 ≥ 3.2† Methotrexate 25 mg/wk + adalimumab 40 mg every 2 weeks
Week 36 ≥ 2.6 and decrease of >
1.2‡
Methotrexate 25 mg/wk + adalimumab 40 mg/week
Week 52 ≥ 3.2† Methotrexate 25 mg/wk + etanercept 50 mg/week
1 year + 3
months
≥ 3.2† Methotrexate 25 mg/wk + infliximab 3 mg/kg every 8 weeks (after a loading dose at weeks
0, 2 and 6)
1 year + 6
months
≥ 2.6 and decrease of >
1.2‡
Methotrexate 25 mg/wk + infliximab 3 mg/kg every 4 weeks
The goal of treatment was remission (Disease Activity Score in 28 joints (DAS28) < 2.6). Treatment was intensified when this target was not met. In case of
remission, medication was not changed. † Following the guidelines of the Dutch Society of Rheumatology and Dutch reimbursement regulations, anti-tumor
necrosis factor a (anti-TNFa) therapy could be prescribed to patients with at least moderate disease activity (DAS28 ≥ 3.2) and in whom treatment with at least
two disease-modifying antirheumatic drugs had failed (including methotrexate at 25 mg/week). ‡ Anti-TNFa therapy could be continued only if the DAS28 had
decreased by > 1.2 after three months.
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Monitoring of disease activity
The DAS28 was available in 97.9% (1,092/1,115) of the
scheduled cohort visits. The main reasons for the DAS28
score being missing were that the ESR was not (yet) avail-
able or the patient’s general health was not assessed (data
not shown). Since the level of disease activity could not be
evaluated in these visits, we could not determine whether
adherence to the medication protocol was accomplished.
Therefore, these 23 visits (2.1%) were excluded from
further analyses.
According to the T2T strategy, disease activity should
be assessed using the DAS28 at least every three
months. In 88.3% (964/1,092) of the visits, this recom-
mendation was met. In the remaining 128 cases, DAS28
remission was present at the previous visit in 71.1% (91/
128), and, therefore, the attending rheumatologist sched-
uled the next visit in six months in 93.4% (85/91) of
these visits.
Adherence treatment advice
Adherence to the treatment advice was observed in 69.3%
(757/1,092) of the visits. Non-adherence at least at one
visit was experienced by 91.0% of patients (91/100).
Remission
Remission was present in 50.6% (553/1,092) of the visits.
The treatment advice was followed in 80.5% (445/553) of
these visits, that is, medication was continued or, in case
of sustained remission (DAS28 < 2.6 for at least six
months), tapered off or discontinued (Figure 1A). The var-
ious deviations in the non-adherence cases (19.5%, 108/
553) are also depicted in Figure 1A. Most frequently, med-
ication was tapered off or discontinued when it should
have been continued according to the treatment advice
(7.2%, 40/553), or treatment was continued when it should
have been tapered off or discontinued (6.2%, 34/553).
Furthermore, medication was intensified in 4.3% (24/553)
in spite of DAS28 remission. In 9 of these 24 cases, the
patient had at least one swollen joint. Other deviations
were observed in 1.8% (10/553). In 12.0% (13/108) of these
non-adherence cases, the deviation concerned anti-TNF
therapy.
The reasons for non-adherence are presented in Table 3.
The most frequently observed reasons for non-adherence
were the presence of active disease according to the rheu-
matologist (that is, based on the presentation of the
patient’s overall disease activity, in particular, the degree of
arthritis) and drug side effects.
Remission according to the provisional ACR/EULAR
definition of remission was observed in 42.9% (237/524)
of these visits (remission could not be evaluated in all
visits due to missing values for CRP).
Non-remission
In case of non-remission, the treatment advice was fol-
lowed in 57.9% (312/539) of the visits (Figure 1B),
meaning that therapy was intensified. Figure 1B also
shows the various deviations in case of non-adherence
(42.1%, 227/539). The most frequently observed devia-
tion was that medication was not intensified (that is,
continued, tapered off or discontinued) when an intensi-
fication step should have been taken according to the
treatment advice (34.9%, 188/539). Other deviations
were observed in 7.2% (39/539). In 21.6% (49/227) of
the non-adherence cases, the deviation concerned anti-
TNF therapy.
In the non-adherence cases, disease activity was low (2.6
≤ DAS28 ≤ 3.2) in 43.2% (98/227), moderate (3.2 < DAS28
Table 2 Description of the characteristics of the 100 rheumatoid arthritis (RA) patients
Age, mean ± SD years 57.7 ± 15.4
Female sex, n (%) 61 (61.0)
Symptom duration, median (IQR) weeks 12.0 (8.0 to 25.0)
Fulfillment of ACR 1987 criteria for RA, n (%) 81/97 (83.5)
RF positive, n (%) 61 (61.0)
Anti-CCP positive, n (%) 58/98 (59.2)
DAS28, mean ± SD 4.9 ± 1.1
No. of swollen joints (28 assessed), median (IQR) 7.0 (4.0 to 12.0)
No. of tender joints (28 assessed), median (IQR) 4.0 (2.0 to 10.0)
ESR, median (IQR) mm/hour 31.2 ± 18.5
CRP, median (IQR) mg/litre 11.5 (5.0 to 30.8)
Patient’s assessment of general health, mean ± SD (0 to 100 VAS) 54.0 ± 22.5
Patient’s assessment of pain, mean ± SD (0 to 100 VAS) 51.7 ± 23.0
HAQ score, mean ± SD 0.9 ± 0.7
SF-36 PCS score, mean ± SD 38.3 ± 10.0
SF-36 MCS score, mean ± SD 47.8 ± 12.6
ACR, American College of Rheumatology; anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR,
erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, interquartile range; MCS, mental component summary; PCS, physical component
summary; RF, rheumatoid factor; SD, standard deviation; SF-36, Short-Form 36 health survey; VAS, visual analog scale
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≤ 5.1) in 49.8% (113/227), and high (DAS28 > 5.1) in 7.0%
(16/227).
Table 3 presents the reasons for non-adherence. The
most frequently observed reason for deviation was that
clinical remission was present according to the rheumatol-
ogist, even though the DAS28 was 2.6 or higher. In these
108 visits, the distribution of the clinical variables was as
follows: median (IQR) SJC28 of 1.0 (0.0 to 3.0), median
(IQR) TJC28 of 0.0 (0.0 to 3.0), mean (SD) ESR of 22.6
(14.9), and median (IQR) CRP of 5.0 (4.0 to 8.0). The
mean (SD) DAS28 was 3.3 (0.7) and 54.6% (59/108) of
these patients had a DAS28 ≤ 3.2. The mean (SD) scores
of the patient’s assessment of pain was 31.6 (21.4) and of
general health 34.6 (21.1).
Non-remission according to the provisional ACR/
EULAR definition of remission was observed in 94.2%
(508/514) of these visits (remission could not be evaluated
in all visits due to missing values for CRP).
Other medication
Disease modifying medication outside the treatment
advice was prescribed in 8.0% (8/100) of the patients; 1
patient received leflunomide and 7 patients received at
least one intra-muscular corticosteroid injection. Predniso-
lone dosages > 10 mg per day were given to 7.0% (7/100)
of the patients at least at one visit.
Drug side effects
Adherence to the treatment advice was prevented by
drug side effects in 71 visits. Table 4 presents the var-
ious side effects that were registered in the medical
charts. If the patient experienced more than one side
effect, we listed only the first reported side effect.
Discussion
This descriptive evaluation demonstrated that a T2T strat-
egy is possible in daily clinical practice. The recommenda-
tions regarding T2T were successfully implemented in the
participating rheumatology clinics of the DREAM remis-
sion induction cohort. Disease activity was regularly and
systematically measured using the DAS28 and adherence
to the treatment advice was high. In case of non-adher-
ence to the recommendations, valid arguments for deviat-
ing were observed in the majority of these cases.
Real-life observational data regarding the adherence to
a T2T strategy in daily clinical practice were analyzed.
These are valuable data because T2T strategies are often
conducted in the setting of randomized controlled trials
(RCTs), which entails a more controlled environment
compared to routine care. This was a retrospective eva-
luation and, therefore, the attending physicians were not
influenced by the goal of this analysis.
A.            B. 
                   Remission (DAS28 <2.6)                                   Non-remission (DAS28 2.6) 
      
 
Figure 1 Adherence to the treatment advice of the treat-to-target strategy. The pie charts illustrate how often the treatment advice was
followed in A) 553 visits in which remission (Disease Activity Score in 28 joints (DAS28) < 2.6) was present and B) 539 visits in which no
remission (DAS28 ≥ 2.6) was present of 100 patients with early rheumatoid arthritis.
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The successful implementation of T2T in the DREAM
hospitals can be explained by several factors. First, the evi-
dence from RCTs and, subsequently, the fact that current
guidelines and recommendations underline the importance
of T2T has raised rheumatologists’ awareness about the
effectiveness of T2T. Second, the recommendations regard-
ing the frequency of monitoring and the therapeutic
regimen in the present study were fit in as close as possible
with the conventional management of RA in daily clinical
practice. Prior to the implementation of T2T, consensus
was reached on the recommendations by all rheumatolo-
gists of the participating hospitals. Third, the organization
of care was arranged as such that the treatment approach
did not require extra effort and time from the rheumatolo-
gist during the clinical visit. Prior to the visit to the rheu-
matologist, RA disease activity according to the DAS28
was evaluated by a trained rheumatology nurse. The rheu-
matology nurses take part in annual DAS28 training ses-
sions, which guarantee the uniformity of the DAS28
assessment. A previous study by Van Hulst et al. suggests
that nurse-led care, including DAS28 measurement, may
be helpful in making DAS28 assessments more feasible for
daily clinical practice settings [13]. Furthermore, general
practitioners are aware of the importance of early referral
of patients with symptoms of arthritis to the rheumatolo-
gist, thereby making an early diagnosis possible.
Table 3 Reasons for non-adherence to the treatment advice of the treat-to-target strategy
Remission
(DAS28 < 2.6)
(n = 553)
Non-remission
(DAS28 ≥ 2.6)
(n = 539)
Tapering off/discontinuing instead of continuing 40 (7.2)
Unknown 12
Patient wish 3
Side effects 19
Clinical remission 5
Other 1
Continuing instead of tapering off/discontinuing 34 (6.2) .
Unknown 23
Patient wish 4
Active disease 5
Other 2
Intensifying instead of not intensifying* 24 (4.3) .
Unknown 2
Patient wish 2
Active disease 20
Not intensifying* instead of intensifying . 188 (34.9)
Unknown 29
Patient wish 13
Side effects 32
Clinical remission 106
Other 8
Other deviations from treatment advice 10 (1.8) 39 (7.2)
Unknown 5 10
Patient wish . 2
Side effects 4 16
Clinical remission . 2
Other 1 9
Data are presented of a total of 1097 visits of 100 patients with early rheumatoid arthritis, stratified by remission state according to the Disease Activity Score in
28 joints (DAS28). Values regarding the type of deviation are presented as number (%), values regarding the reasons for non-adherence are presented as
number. *Including continuing, tapering off and discontinuing medication.
Table 4 Drug side effects (n = 71)
Not defined 23 (32.4)
Abnormal liver function tests 12 (16.9)
Nausea, abdominal pain or diarrhoea 10 (14.1)
Haematological abnormalities 7 (9.9)
Pulmonary problem 7 (9.9)
Mental or mood changes 5 (7.0)
Hair loss 3 (4.2)
Skin rash 2 (2.8)
Vision problem 2 (2.8)
Values are presented as number (%).
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At a percentage of 69%, the observed level of adherence to
the T2T recommendations was probably optimal, as striving
for 100% adherence is not realistic because treatment of
patients is subject to side effects and comorbidities. More-
over, it is obvious that patients are involved in their treat-
ment decision making process. Previous studies have shown
that discordance exists between the patients’ and rheuma-
tologists’ rating of disease activity [29,30] and that they
approach the decision to intensify medication differently
[31,32]. Moreover, patients may be reluctant to change
medications frequently and fear side effects. In the present
study, the main reason for non-adherence was discordance
between disease activity status according to the rheumatolo-
gist and the DAS28, which might be explained by properties
of the DAS28 algorithm. The feet are omitted in the
DAS28; however, disease activity in the foot joints is fre-
quently observed in RA, even in patients who are consid-
ered to be in DAS28 remission [33]. This among other
factors has led to the debate of whether the cut-off point for
DAS28 remission reflects true clinical remission [34,35]. In
the therapeutic decision making, rheumatologists do not
always rely solely on the DAS28 [36], but also other markers
of inflammation and/or progression [31,37] and patients’
characteristics [38] are taken into account. The DAS28 is
suggested to be a tool to guide decision making in RA;
nevertheless, it cannot always replace the clinical judgement
in the context of an individual patient. Therefore, T2T
should be performed with thoughtful consideration.
This study has some drawbacks. First, adherence to the
recommendations of the T2T strategy was evaluated in
only 100 patients of the total cohort, which includes more
than 700 patients at the time of data collection. However, a
random sample was taken which we believe was represen-
tative for the total cohort. Second, it was not explicitly
requested to report the reason for protocol deviations, and,
therefore, not all reasons could be retrieved. Third, this
T2T strategy reflects the effects of only one medication
strategy; no other treatment strategies were included. Sev-
eral therapeutic regimes and treatment approaches have
been introduced over the last decade, but the most optimal
strategy for patients newly diagnosed with RA remains
undecided. Moreover, after the initiation of the DREAM
remission induction cohort, it emerged that the dose
increase of anti-TNF therapy might have limited effective-
ness [39] and also the effectiveness of a third anti-TNF
agent in case of failure of two previous anti-TNF agents
has been debated. This might have led to deviations from
the advised anti-TNF therapy steps. Fourth, it was not
investigated whether failure to be adherent to the strategy
had any impact on whether patients achieved remission.
Conclusions
In conclusion, this study showed that the implementa-
tion of T2T is feasible in very early RA in daily clinical
practice. We demonstrated a high adherence to the T2T
recommendations, which comprised regular assessment
of the DAS28 and treatment advice regarding subse-
quent DAS28-driven therapeutic steps.
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